Sylvia Grunewald
Berlin, BE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis.
Journal: Molecular oncology
Published: August 08, 2023
Correction: Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice.
Journal: European journal of medical research
Published: June 24, 2023
Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice.
Journal: European journal of medical research
Published: September 13, 2022
Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis.
Journal: Journal of hepatology
Published: December 03, 2018
Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.
Journal: International journal of cancer
Published: September 07, 2018
Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance.
Journal: Molecular cancer therapeutics
Published: December 18, 2017
Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity.
Journal: Nature
Published: December 08, 2017
Discovery of Rogaratinib (BAY 1163877): a pan-FGFR Inhibitor.
Journal: ChemMedChem
Published: November 16, 2017
Novel TIE-2 inhibitor BAY-826 displays in vivo efficacy in experimental syngeneic murine glioma models.
Journal: Journal of neurochemistry
Published: August 11, 2016
Capturing tumor complexity in vitro: Comparative analysis of 2D and 3D tumor models for drug discovery.
Journal: Scientific reports
Published: February 02, 2016
Showing 1-10 of 10
Last Updated: 09/26/2026